Cystamine/cysteamine rescues the dopaminergic system and shows neurorestorative properties in an animal model of Parkinson's disease.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Cystamine/cysteamine rescues the dopaminergic system and shows neurorestorative properties in an animal model of Parkinson's disease. / Cisbani, G; Drouin-Ouellet, Janelle; Gibrat, C; Saint-Pierre, M; Lagacé, M; Badrinarayanan, S; Lavallée-Bourget, M H; Charest, J; Chabrat, A; Boivin, L; Lebel, M; Bousquet, M; Lévesque, M; Cicchetti, F.

I: Neurobiology of Disease, Vol. 82, 2015, s. 430-444.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

Cisbani, G, Drouin-Ouellet, J, Gibrat, C, Saint-Pierre, M, Lagacé, M, Badrinarayanan, S, Lavallée-Bourget, MH, Charest, J, Chabrat, A, Boivin, L, Lebel, M, Bousquet, M, Lévesque, M & Cicchetti, F 2015, 'Cystamine/cysteamine rescues the dopaminergic system and shows neurorestorative properties in an animal model of Parkinson's disease.', Neurobiology of Disease, vol. 82, s. 430-444. https://doi.org/10.1016/j.nbd.2015.07.012

APA

Cisbani, G., Drouin-Ouellet, J., Gibrat, C., Saint-Pierre, M., Lagacé, M., Badrinarayanan, S., ... Cicchetti, F. (2015). Cystamine/cysteamine rescues the dopaminergic system and shows neurorestorative properties in an animal model of Parkinson's disease. Neurobiology of Disease, 82, 430-444. https://doi.org/10.1016/j.nbd.2015.07.012

CBE

Cisbani G, Drouin-Ouellet J, Gibrat C, Saint-Pierre M, Lagacé M, Badrinarayanan S, Lavallée-Bourget MH, Charest J, Chabrat A, Boivin L, Lebel M, Bousquet M, Lévesque M, Cicchetti F. 2015. Cystamine/cysteamine rescues the dopaminergic system and shows neurorestorative properties in an animal model of Parkinson's disease. Neurobiology of Disease. 82:430-444. https://doi.org/10.1016/j.nbd.2015.07.012

MLA

Vancouver

Author

Cisbani, G ; Drouin-Ouellet, Janelle ; Gibrat, C ; Saint-Pierre, M ; Lagacé, M ; Badrinarayanan, S ; Lavallée-Bourget, M H ; Charest, J ; Chabrat, A ; Boivin, L ; Lebel, M ; Bousquet, M ; Lévesque, M ; Cicchetti, F. / Cystamine/cysteamine rescues the dopaminergic system and shows neurorestorative properties in an animal model of Parkinson's disease. I: Neurobiology of Disease. 2015 ; Vol. 82. s. 430-444.

RIS

TY - JOUR

T1 - Cystamine/cysteamine rescues the dopaminergic system and shows neurorestorative properties in an animal model of Parkinson's disease.

AU - Cisbani, G

AU - Drouin-Ouellet, Janelle

AU - Gibrat, C

AU - Saint-Pierre, M

AU - Lagacé, M

AU - Badrinarayanan, S

AU - Lavallée-Bourget, M H

AU - Charest, J

AU - Chabrat, A

AU - Boivin, L

AU - Lebel, M

AU - Bousquet, M

AU - Lévesque, M

AU - Cicchetti, F

PY - 2015

Y1 - 2015

N2 - The neuroprotective properties of cystamine identified in pre-clinical studies have fast-tracked this compound to clinical trials in Huntington's disease, showing tolerability and benefits on motor symptoms. We tested whether cystamine could have such properties in a Parkinson's disease murine model and now provide evidence that it can not only prevent the neurodegenerative process but also can reverse motor impairments created by a 6-hydroxydopamine lesion 3weeks post-surgery. Importantly, we report that cystamine has neurorestorative properties 5weeks post-lesion as seen on the number of nigral dopaminergic neurons which is comparable with treatments of cysteamine, the reduced form of cystamine used in the clinic, as well as rasagiline, increasingly prescribed in early parkinsonism. All three compounds induced neurite arborization of the remaining dopaminergic cells which was further confirmed in ex vivo dopaminergic explants derived from Pitx3-GFP mice. The disease-modifying effects displayed by cystamine/cysteamine would encourage clinical testing.

AB - The neuroprotective properties of cystamine identified in pre-clinical studies have fast-tracked this compound to clinical trials in Huntington's disease, showing tolerability and benefits on motor symptoms. We tested whether cystamine could have such properties in a Parkinson's disease murine model and now provide evidence that it can not only prevent the neurodegenerative process but also can reverse motor impairments created by a 6-hydroxydopamine lesion 3weeks post-surgery. Importantly, we report that cystamine has neurorestorative properties 5weeks post-lesion as seen on the number of nigral dopaminergic neurons which is comparable with treatments of cysteamine, the reduced form of cystamine used in the clinic, as well as rasagiline, increasingly prescribed in early parkinsonism. All three compounds induced neurite arborization of the remaining dopaminergic cells which was further confirmed in ex vivo dopaminergic explants derived from Pitx3-GFP mice. The disease-modifying effects displayed by cystamine/cysteamine would encourage clinical testing.

U2 - 10.1016/j.nbd.2015.07.012

DO - 10.1016/j.nbd.2015.07.012

M3 - Article

VL - 82

SP - 430

EP - 444

JO - Neurobiology of Disease

T2 - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

ER -